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Abstract 
Emergence of resistant influenza virus progeny to currently approved antiviral drugs determines the need for 
antiviral susceptibility monitoring. The aim of the present study is to analyze neuraminidase inhibitor 
susceptibility of influenza viruses circulating in Bulgaria during the 2011/2012, 2012/2013, 2013/2014 and 
2014/2015 flu seasons. A phenotypic fluorescence-based assay with MUNANA substrate was conducted with 
93 influenza A(H1N1)pdm09, A(H3N2) and type B isolates. Screening of 352 influenza A(H1N1)pdm09 
viruses was carried out using a Real Time RT-PCR discrimination assay for detection of the H275Y oseltamivir 
resistance point mutation. Phenotypic (IC50) evidence for resistance or reduced susceptibility to neuraminidase 
inhibitors was not found for any of the influenza A(H1N1)pdm09, A(H3N2) and type B viruses screened. Only 
one (0,3%) influenza A(H1N1)pdm09 virus carrying the H275Y substitution was detected. Real Time RT-PCR 
assay could be applied to screen large numbers of clinical A(H1N1)pdm09 influenza virus positive samples for 
oseltamivir resistance. The present study highlights the importance of continued influenza antiviral 
susceptibility monitoring in clinical specimens. 
Keywords: Influenza virus; Resistance; H275Y mutation. 
1. Introduction 
Influenza viruses cause annual epidemics with significant morbidity and mortality, accounting for about 600 
million illness episodes and 250 000-500 000 deaths globally [1].  
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Vaccination remains the most effective means for preventing influenza. Treatment and chemoprophylaxis with 
antiviral drugs are another option for the control of the disease. There are two classes of antiviral drugs currently 
approved in many countries – M2 ion channel inhibitors (rimantadine and amantadine) and neuraminidase 
inhibitors (NAIs) (oseltamivir, zanamivir, peramivir, laninamivir – the last two NAIs are approved in Japan, 
South Korea and USA). The major problem associated with use of antiviral drugs is the emergence of resistant 
viral progeny among circulating influenza viruses due to subtype- and inhibitor-specific point mutations in the 
M2 or neuraminidase (NA) virus genes. Numerous resistance-associated amino acid substitutions have been 
identified in the different influenza virus types and sub-types that lead to the reduction or complete loss of drug 
effectiveness [2, 3, 4]. As adamantanes resistance among currently circulating influenza A viruses is widespread 
(>99%) and having in mind the ineffectiveness of adamantanes against influenza B viruses, these drugs 
nowadays are not strongly recommended for treatment or prevention of influenza. Antiviral resistance to 
neuraminidase inhibitors among circulating influenza viruses is currently low, but resistant virus progeny can 
always emerge and antiviral treatment could enhance the selection of resistant virus strains. Since resistant 
influenza viruses could rapidly spread and displace virus strains susceptible to antiviral drugs, the World Health 
Organization (WHO) encourages monitoring antiviral drug susceptibility of circulating influenza viruses. For 
this purpose, various methods have been used, both - phenotypic (functional) and genotypic [5, 6].  
Phenotypic assays (fluorescent, chemiluminescent, etc.) measure the concentration of drug required to inhibit 
neuraminidase activity of the virus by 50% (ie inhibitory concentration, IC50). These methods evaluate the 
impact of multiple mutations – either known or novel, leading to the emergence of a resistant phenotype. 
Phenotypic analysis is widely accepted as the “gold standard” for detecting influenza virus drug resistance, 
however, the assays are lengthy, labor-intensive; require high titer cultured viruses, expensive equipment and 
reagents. Genotypic techniques (Real Time RT-PCR, single-nucleotide polymorphism assays, Sanger 
sequencing, pyrosequencing) can be carried out directly with clinical specimens thus eliminating the need for 
virus propagation in cell culture. PCR based genotypic assays are fast, highly sensitive, lower cost assays which, 
however, can identify the presence of a single known molecular markers of NAI resistance. There are real-time 
RT-PCR assays specially designed for detection of the point mutation in the influenza A(H1N1) neuraminidase 
gene that results in a tyrosine to histidine substitution at amino acid position 275 (H275Y) and which results in 
clinical resistance to oseltamivir but not to zanamivir [7, 8, 9]. This is the most commonly detected oseltamivir-
resistance mutation in N1-containing viruses.  
The purpose of the present study is to determine the frequence of pandemic A(H1N1)pdm09 viruses harbouring 
the resistance H275Y mutation and characterization of the phenotypic NAI susceptibility of influenza viruses 
circulating in Bulgaria during the last four consecutive epidemic seasons (2011/12 to 2014/15). 
2. Materials and Methods 
2.1. Patients and specimens 
Clinical specimens (nasal and throat swabs) were collected from patients presenting with symptoms of 
influenza-like illness (ILI) or acute respiratory illness (ARI) in different regions of the country during the 
2011/2012, 2012/2013, 2013/2014 and 2014/2015 winter seasons.  
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2.2. Real Time RT-PCR for detection and typing/subtyping of influenza viruses 
Viral nucleic acids were automatically extracted from the respiratory specimens using a commercial ExiPrep Dx 
Viral DNA/RNA kit (Bioneer, Korea) according to the manufacturer’s instruction. Detection and 
typing/subtyping of influenza viruses was carried out by the Real Time RT-PCR method with the use of a kit - 
SuperScript III Platinum ® One-Step Quantitative RT-PCR System (Invitrogen). All specimens were initially 
tested for the presence of influenza A and B viruses, and those positive for influenza A were subsequently tested 
for A(H1N1)pdm09 and A(H3N2). Primers, probes and positive controls for influenza A/B viruses were 
provided by the US CDC-Atlanta. Amplification was performed with a Chromo 4 thermal cycler (Bio-Rad) 
according to the protocol of CDC [10]. A Ct value <38 was regarded as positive. 
2.3. Isolation of influenza viruses 
Isolation of influenza viruses from PCR-confirmed clinical specimens was carried out on MDCK (Madin-Darby 
Canine Kidney) and MDCK-SIAT (over-expressing SA2, 6Gal receptor) cell cultures following standard 
techniques [11]. Clinical samples were inoculated onto cell cultures and passaged twice to reach sufficient titers 
for NA inhibition testing. Propagation of influenza viruses in cell cultures was confirmed by implementation of 
the hemagglutination reaction in culture supernatants. 
2.4. Neuraminidase inhibition assay 
Neuraminidase activity and drugs susceptibility were determined in the World Health Organization 
Collaborating Centre (WHO-CC), London by phenotypic fluorescence-based method. The assay is based on 
biochemical NA inhibition using small synthetic sialic acid conjugate as a substrate–2’-O-(4-
methylumbelliferyl)-N-acetylneuraminic acid (MUNANA) resulting in a fluorescent signal upon cleavage by 
the viral NA surface protein. The assay determines the concentration of NAI required to inhibit NA activity by 
50% as compared to a mixture containing virus but no inhibitor (IC50 value) [11]. Phenotypic NAI susceptibility 
of influenza A viruses was evaluated based on the fold-change in IC50 values compared to that in susceptible 
reference virus from the same NA subtype/lineage: “normal inhibition” (<10-fold increase); “reduced 
inhibition” (10–100-fold increase); “highly reduced inhibition” (>100-fold increase); for influenza B a similar 
criterion was used but interpretation values were as follows: <5-fold, 5–50-fold and >50-fold increases, 
respectively [4, 12]. Briefly, isolated viruses were incubated in the presence of a range of different oseltamivir 
or zanamivir concentrations at 370C for 30 min. 2-(4-Methylumbelliferyl)-a-D-N-acetylneuraminic acid 
(MUNANA; Sigma–Aldrich) was added at a final concentration of 100 μM and the mixture was incubated at 
370C for 60 min. The reaction was stopped by the addition of 150 μL stop solution. The plates were read using 
96 well fluorescence plate reader (Biotek, Synergy 2 Multi-Mode Microplate Reader) at 355 nm (excitation 
wavelength) and 460 nm (emission wavelength) and the IC50 of each virus was determined. The mean IC50 value 
was calculated from two independent experiments in duplicates. 
2.5. Real Time RT-PCR for detection of H275Y point mutation 
Clinical samples containing A(H1N1)pdm09 viruses that failed to be cultured were tested for the presence of 
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H275Y mutation using Real Time RT-PCR. In this assay two probes differing in position 823 of the NA gene 
were simultaneously used: the first probe contains a cytosine at position 823 and was  labeled with VIC (H275), 
while the second probe contains thymine in the same position and was labeled with FAM (275Y). Primer/probe 
sequences and protocol were kindly provided by Health Protection England (HPE), London. The 
A(H1N1)pdm09 H275Y assay alloweds discrimination of a single nucleotide difference between oseltamivir 
sensitive and resistant viruses using TaqMan probes. Influenza viruses A/Denmark/524/2009 (sensitive, H275) 
and A/Denmark/528/2009 (resistant, 275Y) received from WHO-CC in London were used as positive controls. 
3. Results 
Clinical specimens (throat and nasal swab) of 3717 patients collected during the last four winter seasons 
(2011/2012 to 2014/2015), were tested for influenza viruses using Real Time RT-PCR. A total of 1194 (32%) 
specimens proved positive for influenza viruses, of which 884 (74%) were typed as influenza A and 310 (26%) 
as influenza B. Of the sub-typed seasonal influenza A viruses, 352 (41%) were influenza A(H1N1)pdm09 and 
508 (59%) were influenza A(H3N2) virus. Co-circulation of all seasonal influenza types/ subtypes had been 
registered during each season, with the exception of A(H1N1)pdm09 virus in 2011/12 season. 
During seasons included in the study, 56 influenza A(H1N1)pdm09, 24 A(H3N2) and 13 type B viruses were 
isolated on cell cultures and submitted to the WHO-CC, London. The number of A(H3N2) isolates was less due 
to the emergence of A(H3N2) viruses that failed to efficiently agglutinate guinea-pig red blood cells. Frequency 
of A(H3N2) strains with low hemagglutination activity has increased since 2011/12 season. 
 
3.1. Phenotypic susceptibility of influenza viruses to NAIs 
 
A total of 93 influenza viruses - 56 A(H1N1)pdm09, 24 A(H3N2) and 13 type B were examined in the 
fluorescent NA inhibition assay. The NAI susceptibility of influenza viruses isolated in Bulgaria is shown in 
Table 1. All tested viruses displayed normal inhibition by oseltamivir and zanamivir (IC50-fold increase <10 in 
comparison to susceptible reference virus of the same NA subtype/lineage). Mean IC50 values of oseltamivir 
and zanamivir among type A viruses - A(H1N1)pdm09 and A(H3N2) were low. Zanamivir had lower mean 
IC50 value for A(H1N1)pdm09 isolates as compared to values for A(H3N2) viruses. Oseltamivir IC50 values 
for type B viruses were significantly higher ranging between 6,95 and 36,16 nM. 
 
3.2. Screening of influenza A(H1N1)pdm09 viruses for H275Y point mutation 
 
During the 2012/2013, 2013/2014 and 2014/2015 winter seasons a total of 348 influenza A(H1N1)pdm09 
viruses were tested using a Real Time RT-PCR method for detection of single point mutation in the NA virus 
gene that results in H275Y amino acid substitution. Only one sample from 2013/2014 season contained this 
mutation (Table 2). In this sample a positive signal was obtained with both a fluorescent dye-labeled probes 
which meant that the viral population comprised a mixture of sensitive and resistant viruses. The H275Y 
harbouring virus was detected in a 4 months old immunocompetent child diagnosed with meningitis treated with 
oseltamivir. The clinical specimen was obtained after the second drug dose. The resistant mutant virus failed to 
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be cultured and therefore no IC50 value was determined. 
 
 
Table 1: NAI susceptibility of influenza viruses determined by the fluorescent NA inhibition assay 
Viruses 
IC50 values of NAIs 
Oseltamivir Zanamivir 
No of 
isolates 
analyzed 
Mean 
IC50± SD*, 
(nM) 
Min 
IC50 
(nM) 
Max 
IC50 
(nM) 
No of 
isolates 
analyzed 
Mean 
IC50± SD, 
(nM) 
Min 
IC50 
(nM) 
Max 
IC50 
(nM) 
A(H1N1)pdm09 56 1,96±1,42 0,35 7,72 56 0,38±0,24 0,09 1,08 
A(H3N2) 24 1,18±0,30 0,81 1,86 24 1,00±0,31 0,54 1,45 
Type B 13 21,40±6,68 6,95 36,16 13 1.16±0,43 0,6 2,25 
*Standard Deviation 
 
Table 2: Results of Real Time RT-PCR for detection of H275Y point mutation 
Seasons Number of A(H1N1)pdm09 
viruses tested 
Number of H275Y 
viruses detected 
2011/2012 - - 
2012/2013 60 0 
2013/2014 261 1 (0,4%) 
2014/2015 31 0 
Total 352 1 (0,3%) 
 
4. Discussion 
 
Testing influenza virus susceptibility to available antiviral drugs is important and recommended by WHO 
because the probability of occurrence and possible widespread of resistant virus strains with easy 
transmissibility, and capable of displacing sensitive strains, thus becoming dominant. The latter could lead to 
exhaustion of the potentialities for specific influenza treatment, which at present is limited to the use of 
neuraminidase inhibitors, i. e. oseltamivir, zanamivir, peramivir and laninamivir. 
 
In the present study, the susceptibility of influenza A(H1N1)pdm09, A(H3N2) and type B viruses to NAIs 
(oseltamivir and zanamivir) is described and examined using a phenotypic fluorescence-based method and Real 
Time RT-PCR during the last four consecutive influenza seasons (from 2011/2012 to 2014/2015). Phenotypic 
(functional) approaches are well-established tools, which allow determination of the effect of different 
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mutations (both known and novel) on the sensitivity of different influenza virus types and subtypes to NAIs. All 
93 newly isolated influenza viruses tested by the fluorescence-based phenotypic method were sensitive to 
oseltamivir and zanamivir. Our findings are in accordance with surveillance data in other countries [13, 14, 15]. 
The need to obtain high titer viral cultures in order to apply the procedure, restricts the opportunity for a wider 
use of phenotypic methods. Furthermore, emergence of influenza A(H3N2) viruses displaying poor 
hemagglutination activity has been observed since 2011/12 season. The inefficient hemagglutination activity of 
A(H3N2) strains further hampers the obtaining of virus isolates with sufficiently high titer. 
 
As it is known, H275Y mutation causes high-level clinical resistance to oseltamivir but not to zanamivir in 
influenza A(H1N1) viruses. The vast majority of oseltamivir–resistant influenza A(H1N1) viruses harbors the 
mutation. Human A(H1N1) influenza viruses carrying H275Y substitution suddenly emerged in 2007/2008 
winter season in the Northern hemisphere and quickly became the dominant circulating strains in many 
countries [16]. At present, incidence of H275Y mutation among pandemic A(H1N1)pdm09 viruses that 
completely replaced seasonal influenza viruses of the same subtype is very low. Global surveillance reveals that 
the frequency of oseltamivir-resistant A(H1N1)pdm09 viruses is about 1% and 3% in 2012/2013 and 2013/2014 
influenza seasons, respectively [17, 18]. Although the overall frequency of NAI-resistance markers among 
A(H1N1)pdm09 viruses is very low, oseltamivir resistance could emerge due to both mutations in the NA gene, 
or to reassortment within the resistant virus. Therefore, oseltamivir susceptibility monitoring of pandemic 
viruses is very important especially given the fact that oseltamivir nowadays is the most commonly prescribed 
antiviral drug against influenza. The extensive screening of 348 A(H1N1)pdm09 viruses by Real Time RT-PCR 
presented here, identified only one virus that possessed the H275Y mutation. The H275Y virus was detected in a 
patient receiving oseltamivir treatment, which suggests that the drug was responsible for the selection of this 
mutant virus. Detection of H275Y mutants in specimens collected during or after drug therapy is also observed 
in other reports [19]. These findings emphasize the importance of H275Y mutation monitoring during the 
treatment course with a view to possible change of antiviral drug. The Real Time RT-PCR method used here 
allowed the rapid resistance testing of a large numbers of clinical samples with a short turnaround time (3-4 h) 
and at a relatively low cost. The assay is capable detecting 3% H275Y mutants in a mixed influenza 
A(H1N1)pdm09 virus population.  
 
5. Conclusion 
 
To summarize, frequency of influenza A(H1N1)pdm09 viruses harboring the H275Y mutation was very low. 
No resistance or reduced susceptibility to oseltamivir and zanamivir was found among isolated influenza 
A(H1N1)pdm09, A(H3N2) and type B viruses. Continuous surveillance of influenza virus susceptibility to NAIs 
is necessary in parallel with assessment of clinical effectiveness of each NAI. 
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